Skip to main content

Unfortunately we don't fully support your browser. If you have the option to, please upgrade to a newer version or use Mozilla Firefox, Microsoft Edge, Google Chrome, or Safari 14 or newer. If you are unable to, and need support, please send us your feedback.

We'd appreciate your feedback.Tell us what you think! opens in new tab/window

Elsevier
Publish with us
AI-Generated response:

What are the alternative treatments for carcinoid crisis if the efficacy of octreotide is questionable?

Answer generated on June 4, 2024

The AI-generated responses are for illustration purposes only and should not be used for medical purposes.

Alternative treatments for carcinoid crisis, if octreotide's efficacy is questionable, include lanreotide, interferon alfa, and vasopressors.

  • Lanreotide, another somatostatin analogue, can be used similarly to octreotide for symptom control in carcinoid syndrome.[1]

  • Interferon alfa may be added to control symptoms unresponsive to somatostatin analogues.[2]

  • Vasopressors have been shown to be effective as a first-line treatment for intraoperative carcinoid crisis, leading to shorter crisis durations and fewer crises.[3]

  • Additional supportive treatments include H1 and H2 receptor antagonists for flushing, and aminophylline or albuterol for bronchospasm.[2]

  • Telotristat ethyl, a tryptophan hydroxylase inhibitor, is approved for use in combination with somatostatin analogues for diarrhea not adequately controlled by these analogues alone.[2]

Additional info

When considering alternative treatments for carcinoid crisis, it's important to evaluate the specific needs and response patterns of the patient. Lanreotide offers a similar mechanism of action to octreotide and might be preferable due to its longer dosing interval, potentially improving patient compliance. Interferon alfa can be a valuable addition for patients who do not respond adequately to somatostatin analogues alone. The use of vasopressors, particularly in the intraoperative setting, has been highlighted as effective, especially when traditional treatments with octreotide are not sufficient. This approach can be crucial in managing the acute phases of carcinoid crisis effectively. Additionally, the combination of telotristat ethyl with somatostatin analogues provides a targeted approach to managing specific symptoms such as severe diarrhea, which is often a challenging aspect of carcinoid syndrome management. Each of these treatments should be considered within the context of the patient's overall health status and in coordination with other ongoing treatments to ensure the best possible outcome.

References

Reference 1

1.

Elsevier ClinicalKey Drug Monograph

Content last updated: May 2, 2024.

Description Lanreotide is an analog of the naturally occurring hormone somatostatin. Lanreotide is used to normalize growth hormone (GH) and insulin growth factor-1 (IGF-1) concentrations in patients with acromegaly who either have had an inadequate response to surgery or radiotherapy or are not candidates for such modes of treatment. Clinical studies of lanreotide for acromegaly demonstrate that, after approximately 1 year of treatment, 51% to 86% of patients experience decreases of GH concentrations to within normal limits and 38% to 41% experience normalization of both GH and IGF-1 concentrations. Similar to octreotide, lanreotide is also used to minimize the symptoms associated with carcinoid neuroendocrine tumors (NET) including diarrhea, abdominal pain, and flushing. Data indicate that lanreotide exhibits antiproliferative effects on these NET tumors. Lanreotide is also used to treat the symptoms of hyperthyroidism in patients with TSH-secreting pituitary tumors.

Reference 2

2.

Elsevier ClinicalKey Derived Clinical Overview

• Surgical resection of the tumor can be curative if the tumor is localized or palliative and results in prolonged asymptomatic periods if metastases are present. Surgical manipulation of the tumor can, however, cause severe vasomotor abnormalities and bronchospasm (carcinoid crisis). • Percutaneous embolization and ligation of the hepatic artery can decrease the bulk of the tumor in the liver and provide palliative treatment of tumors with hepatic metastases. • Cytotoxic chemotherapy: Combination chemotherapy with 5-fluorouracil and streptozocin can be used in patients with unresectable or recurrent carcinoid tumors; however, it has only limited success. Control of clinical manifestations: 1.000000000000000e+00 Somatostatin analogues (octreotide and lanreotide) are effective for both flushing and diarrhea in most patients. Telotristat ethyl, a tryptophan hydroxylase inhibitor is FDA approved for use in combination with somatostatin analogues (SSAs) for diarrhea inadequately controlled with SSAs. 2.000000000000000e+00 Flushing may be controlled by the combination of H1- and H2-receptor antagonists (e.g., diphenhydramine 25 to 50 mg PO q6h and famotidine 40 mg qd). 3.000000000000000e+00 Diarrhea may respond to diphenoxylate with atropine (Lomotil). 4.000000000000000e+00 Bronchospasm can be treated with aminophylline and/or albuterol. • Nutritional support: Supplemental niacin therapy may be useful to prevent pellagra because the tumor uses dietary tryptophan for serotonin synthesis, resulting in a nutritional deficiency in some patients. • Interferon alfa may be useful as an additive to control symptoms unresponsive to somatostatin analogues.

• Interferon alfa may be useful as an additive to control symptoms unresponsive to somatostatin analogues. • Echocardiography and monitoring for right-sided congestive heart failure are recommended for patients with unresectable disease because endocardial fibrosis, involving predominantly the endocardium, chordae, and valves of the right side of the heart, can occur.

Reference 3

3.

McCully BH, Kozuma K, Pommier S, Pommier RF. Annals of Surgical Oncology. 2024;. doi:10.1245/s10434-023-14876-4.

Publish date: January 2, 2024.

Patients treated with vasopressors were less likely to have multiple crises and had a shorter total time in crisis, a shorter anesthesia time, and no aborted operations (p < 0.05 for all). CONCLUSIONS: First-line octreotide was ineffective treatment for carcinoid crisis, with patients requiring vasopressors to resolve the crisis, and many crises lasting longer than 10 min. First-line vasopressor treatment resulted in significantly shorter crisis durations, fewer crises and aborted operations, and shorter anesthesia times. Vasopressors should be used as first-line treatment for intraoperative crisis, and treatment guidelines should be changed.

Follow up questions